Psychiatrists rank Lilly tops in survey
Executive Summary
Eli Lilly garnered the most votes from psychiatrists as a company they hold in high esteem in Verispan's Pharmaceutical Company Image 2008 study. Lilly was mentioned by 43 percent of the 422 psychiatrists surveyed; the second through fifth place holders were Pfizer, Johnson & Johnson, AstraZeneca and Forest. Increased visits by Lilly sales reps could have something to do with Lilly supplanting Pfizer, which held the top spot in the 2006 survey; a selling audit by Verispan found Lilly's calls to psychiatrists were up almost 25 percent for the 12 months ending in March 2008 compared to the 12 months ending in March 2006
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.